Boston Scientific slides as investors digest lowered 2026 outlook and recall overhang
Boston Scientific shares fell about 3% on April 28, 2026 as investors continued to reprice the stock after the company cut its 2026 outlook last week despite a Q1 sales beat. Ongoing concerns about procedural demand and product-related headlines, including a Class I recall for certain AXIOS stent delivery systems, are weighing on sentiment.
1) What’s moving the stock
Boston Scientific (BSX) is down about 3% today (April 28, 2026) as the market continues to digest last week’s guidance reset. The company reported first-quarter results on April 22 showing net sales of $5.203 billion, but paired the quarter with a reduced 2026 outlook—an outcome that has kept near-term sentiment fragile and has prompted price-target trims in the days since.
2) Why investors are still selling after the print
The selling pressure reflects a “reset” dynamic: even when quarterly results beat expectations, a cut to full-year profit and growth assumptions tends to anchor valuation lower until investors can see stabilization in demand trends and execution. In BSX’s case, the lowered 2026 view has raised questions about whether headwinds are temporary or indicative of a softer trajectory into the second quarter and beyond.
3) Additional overhang: device recall headline risk
Beyond the guidance cut, Boston Scientific has also faced product-related headline risk. The FDA issued and updated a safety communication around Boston Scientific’s removal of certain AXIOS stents and electrocautery-enhanced delivery systems, classifying the issue as a Class I recall (the most serious category) in late February 2026—an ongoing factor that can pressure sentiment even if the financial impact is ultimately limited.
4) What to watch next
Investors will likely focus on whether management can defend the updated 2026 framework with improving monthly procedure trends, clearer segment-level momentum, and any incremental disclosure on recall scope, remediation progress, and potential costs. A stabilization in analyst actions (fewer target cuts) and signs that guidance is now conservatively set would be key catalysts for the stock to find a floor.